Channels Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study
Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC: A Case Report
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC)
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
Treatment‐Emergent Isolated EGFR C797S Mutation Following First‐Line Osimertinib‐Based Combination Therapy: A Case Report and Literature Review
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
An unusual case of focal seizures after a therapeutic dose of isoniazid: a case report
Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions
Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report
A Real-World Evaluation of Therapeutic Inertia in Patients with Severe Uncontrolled Chronic Obstructive Pulmonary Disease
Are Real-World Mobility Patterns Early Indicators of COPD Onset? Insights from Wrist-Worn Sensors
A Real-World Evaluation of Therapeutic Inertia in Patients with Severe Uncontrolled Chronic Obstructive Pulmonary Disease [Letter]
Navigating the Future of Respiratory Infections: Key Insights From International Congress in Singapore, 17–20 September 2025
Reduced‐Dose Dabrafenib–Trametinib for BRAF V600E–Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2
Efficacy and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Single-Center Real-World Study
Emphysema Phenotype and 1‑Year Readmission Risk After Acute Exacerbation of COPD: A Real-World Study Using Propensity Score-Based Methods
